An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye ...

Diabetic retinopathy and diabetic macular edema (DME) are two of the most common vision conditions related to diabetes. They affect about 1 in 4 people with type 1 and type 2 diabetes.

However, left untreated, diabetic retinopathy will steadily get worse over time and start to affect your vision. Treatment can help prevent, delay, and reduce vision loss.

This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...

Regarding diabetic retinopathy’s prevalence, , there are 40 million Americans who have diabetes, and about 60% of them of them will go on to get diabetic eye disease.

An automated grading system for detection of vision-threatening referable diabetic retinopathy on the basis of color fundus photographs. Diabetes Care. 2018;41 (12):2509-2516. doi: 10.2337/dc18-0147.

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.